Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hematologic Malignancies: early-phase trial registry
22 of 46 indexed Hematologic Malignancies trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #312 of 28,707 conditions by registered trial count.
46 US clinical trials · 22 currently recruiting · #312 of 28,707 conditions by registered trial count
Hematologic Malignancies: 46 US clinical trials tracked, 22 recruiting.
Hematologic Malignancies is the subject of 46 registered US clinical trials on ClinicalTrials.gov, 22 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 4 of these trials.
Enrollment posture brief
Registry condition hematologic-malignancies
OPEN 22 | RECR 48% | LATE 3 | EARLY 33 | RANK #312 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Breast Cancer Stage II (48% recruiting · 23 trials)
Hematologic Malignancies lists 22 open slots (48% of 46 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hematologic Malignancies on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hematologic Malignancies is recruiting above its size-band peers.
22 of 46 indexed trials (47.8%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hematologic Malignancies trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 4 of 46 trials (8.7%). 36 distinct sponsors appear on at least one study for this condition label.
-
Most Hematologic Malignancies trials plan to enrol fewer than 100 people.
Median target enrolment is 55 among the 46 trials that report a genuine target (sentinel values excluded). 29 of those (63%) plan for fewer than 100 participants.
-
Hematologic Malignancies research is mostly interventional.
41 interventional and 5 observational studies make up this index (89.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
46 total, page 1 of 1
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Center for International Blood and Marrow Transplant Research
NCT01351545
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Merck Sharp & Dohme
NCT03486873
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
UNC Lineberger Comprehensive Cancer Center
NCT06296368
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Merck Sharp & Dohme
NCT04728893
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
NCT07195916
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
National Cancer Institute (NCI)
NCT05470491
Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy
City of Hope Medical Center
NCT07186192
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
NCT04588922
Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA-Haploidentical Hematopoietic Cell Transplantation
National Cancer Institute (NCI)
NCT07162038
IVIG for Infection Prevention After CAR-T-Cell Therapy
Fred Hutchinson Cancer Center
NCT05952804
Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax
National Heart, Lung, and Blood Institute (NHLBI)
NCT05724121
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
Kumquat Biosciences
NCT06645886
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Immunome
NCT06823167
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Pulmotect
NCT06665100
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
Ascentage Pharma Group
NCT03537482
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
University of California, Irvine
NCT06028828
A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT07359859
Prophylactic TCRaB+ and CD19+ Depleted Donor Lymphocyte Infusion After Allogeneic Stem Cell Transplant in High-Risk Patients With Hematologic Malignancies
University of Wisconsin, Madison
NCT07285668
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
M.D. Anderson Cancer Center
NCT06807606
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
Ronald Paquette
NCT05849207
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
Acrotech Biopharma
NCT07036133
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
AbbVie
NCT03557619
Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study
Mayo Clinic
NCT02457962
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Weill Medical College of Cornell University
NCT01810588
Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies with Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device
Julie-An M. Talano
NCT02600208
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
Memorial Sloan Kettering Cancer Center
NCT04098393
Associations Between Pre-transplant Comorbidities and Post-transplant Toxicities and Quality of Life
Fred Hutchinson Cancer Center
NCT01930981
Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED)
Merck Sharp & Dohme
NCT00086125
Adult Double Cord Blood Transplant Study
Center for International Blood and Marrow Transplant Research
NCT00514579
Allogeneic Bone Marrow Transplantation With Matched Unrelated Donors for Patients With Hematologic Malignancies
Emory University
NCT00208923
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
University of Michigan Rogel Cancer Center
NCT02145403
Infection Rates of Myeloablative Allo SCT Recipients Receiving Neutropenic Diets Versus Non-Neutropenic Diets
Duke University
NCT01687231
A Study Of PF-04449913 In Select Hematologic Malignancies
Pfizer
NCT00953758
Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC)
M.D. Anderson Cancer Center
NCT00750737
Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT00369226
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia
Healios K.K.
NCT00677859
Haploidentical Hematopoietic Stem Cell Transplantation Using A Novel Clofarabine Containing Conditioning Regimen For Patients With Refractory Hematologic Malignancies
St. Jude Children's Research Hospital
NCT00824135
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02342613
IUdR/BUdR Cell Cycle Labelling
M.D. Anderson Cancer Center
NCT00042250
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT00429143
Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
University of California, San Francisco
NCT03609827
Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Patients With Advanced Hematologic Malignancies
Prescient Therapeutics
NCT00642031
Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies
M.D. Anderson Cancer Center
NCT00061620
A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
Yale University
NCT00402714
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
Case Comprehensive Cancer Center
NCT02129582
Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)
Emory University
NCT00231309
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 21 |
| Phase 2 | 12 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Hematologic Malignancies records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hematologic Malignancies trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hematologic Malignancies page
46 registered trials, 22 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 22 Hematologic Malignancies trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Hematologic Malignancies trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hematologic Malignancies condition card totals 46 registered trials; most-linked intervention Tacrolimus; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.